The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome

Cindy Meun; Marlise N. Gunning; Yvonne, V Louwers; Henrike Peters; Jolien Roos-Hesselink; Jeanine Roeters van Lennep; Oscar-Leonel Rueda Ochoa; Yolande Appelman; Nils Lambalk; Eric Boersma; Maryam Kavousi; Bart C. J. M. Fauser; Joop S. E. Laven; Sara Baart; Laura Benschop; Laura Brouwers; Ricardo Budde; Suzanne Cannegieter; Veerle Dam; Rene Eijkemans; Bart C. J. M. Fauser; Michel Ferrari; Arie Franx; Christianne de Groot; Marlise N. Gunning; Annemieke Hoek; Erik Koffijberg; Wendy Koster; Mark Kruit; Giske Lagerweij; Joop Laven; Katie Linstra; Aad van der Lugt; Angela Maas; Antoinette Maassen van den Brink; Saskia Middeldorp; Karel G. M. Moons; Bas van Rijn; Luuk Scheres; Yvonne T. van der Schouw; Eric Steegers; Regine Steegers; Gisela Terwindt; Birgitta Velthuis; Marieke Wermer; Bart Zick; Gerbrand Zoet

doi:10.1111/cen.14117

The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome

Cindy Meun, Marlise N. Gunning, Yvonne, V Louwers, Henrike Peters, Jolien Roos-Hesselink, Jeanine Roeters van Lennep, Oscar-Leonel Rueda Ochoa, Yolande Appelman, Nils Lambalk, Eric Boersma, Maryam Kavousi, Bart C. J. M. Fauser, Joop S. E. Laven, Sara Baart, Laura Benschop, Laura Brouwers, Ricardo Budde, Suzanne Cannegieter, Veerle Dam, Rene EijkemansBart C. J. M. Fauser, Michel Ferrari, Arie Franx, Christianne de Groot, Marlise N. Gunning, Annemieke Hoek, Erik Koffijberg, Wendy Koster, Mark Kruit, Giske Lagerweij, Joop Laven, Katie Linstra, Aad van der Lugt, Angela Maas, Antoinette Maassen van den Brink, Saskia Middeldorp, Karel G. M. Moons, Bas van Rijn, Luuk Scheres, Yvonne T. van der Schouw, Eric Steegers, Regine Steegers, Gisela Terwindt, Birgitta Velthuis, Marieke Wermer, Bart Zick, Gerbrand Zoet

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

OBJECTIVES: Contradictory results have been reported regarding the association between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD). We assessed the cardiometabolic phenotype and prevalence of CVD in middle-aged women with PCOS, compared with age-matched controls from the general population, and estimated 10-year CVD risk and cardiovascular health score.

DESIGN: A cross-sectional study.

PARTICIPANTS: 200 women aged >45 with PCOS, and 200 age-matched controls.

MEASUREMENTS: Anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes. Ten-year Framingham risk score and the cardiovascular health score were calculated, and carotid intima-media thickness (cIMT) was measured.

RESULTS: Mean age was 50.5 years (SD = 5.5) in women with PCOS and 51.0 years (SD = 5.2) in controls. Increased waist circumference, body mass index and hypertension were more often observed in women with PCOS (P < .001). In women with PCOS, the prevalence of type II diabetes and metabolic syndrome was not significantly increased and lipid levels were not different from controls. cIMT was lower in women with PCOS (P < .001). Calculated cardiovascular health and 10-year CVD risk were similar in women with PCOS and controls.

CONCLUSIONS: Middle-aged women with PCOS exhibit only a moderately unfavourable cardiometabolic profile compared to age-matched controls, even though they present with an increased BMI and waist circumference. Furthermore, we found no evidence for increased (10-year) CVD risk or more severe atherosclerosis compared with controls from the general population. Long-term follow-up of women with PCOS is necessary to provide a definitive answer concerning long-term risk for CVD.

Original language	English
Pages (from-to)	150-158
Number of pages	9
Journal	Clinical Endocrinology
Volume	92
Issue number	2
DOIs	https://doi.org/10.1111/cen.14117
Publication status	Published - 1 Feb 2020

Keywords

cardiovascular disease (7)
polycystic ovary syndrome

Access to Document

10.1111/cen.14117

Meun_et_al-2020-Clinical_EndocrinologyFinal published version, 485 KB

Cite this

Meun, C., Gunning, M. N., Louwers, Y. V., Peters, H., Roos-Hesselink, J., van Lennep, J. R., Rueda Ochoa, O.-L., Appelman, Y., Lambalk, N., Boersma, E., Kavousi, M., Fauser, B. C. J. M., Laven, J. S. E., Baart, S., Benschop, L., Brouwers, L., Budde, R., Cannegieter, S., Dam, V., ... Zoet, G. (2020). The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome. Clinical Endocrinology, 92(2), 150-158. https://doi.org/10.1111/cen.14117

@article{87bcc976d5544266a261746911975bd1,

title = "The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome",

abstract = "OBJECTIVES: Contradictory results have been reported regarding the association between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD). We assessed the cardiometabolic phenotype and prevalence of CVD in middle-aged women with PCOS, compared with age-matched controls from the general population, and estimated 10-year CVD risk and cardiovascular health score.DESIGN: A cross-sectional study.PARTICIPANTS: 200 women aged >45 with PCOS, and 200 age-matched controls.MEASUREMENTS: Anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes. Ten-year Framingham risk score and the cardiovascular health score were calculated, and carotid intima-media thickness (cIMT) was measured.RESULTS: Mean age was 50.5 years (SD = 5.5) in women with PCOS and 51.0 years (SD = 5.2) in controls. Increased waist circumference, body mass index and hypertension were more often observed in women with PCOS (P < .001). In women with PCOS, the prevalence of type II diabetes and metabolic syndrome was not significantly increased and lipid levels were not different from controls. cIMT was lower in women with PCOS (P < .001). Calculated cardiovascular health and 10-year CVD risk were similar in women with PCOS and controls.CONCLUSIONS: Middle-aged women with PCOS exhibit only a moderately unfavourable cardiometabolic profile compared to age-matched controls, even though they present with an increased BMI and waist circumference. Furthermore, we found no evidence for increased (10-year) CVD risk or more severe atherosclerosis compared with controls from the general population. Long-term follow-up of women with PCOS is necessary to provide a definitive answer concerning long-term risk for CVD.",

keywords = "cardiovascular disease (7), polycystic ovary syndrome",

author = "Cindy Meun and Gunning, {Marlise N.} and Louwers, {Yvonne, V} and Henrike Peters and Jolien Roos-Hesselink and {van Lennep}, {Jeanine Roeters} and {Rueda Ochoa}, Oscar-Leonel and Yolande Appelman and Nils Lambalk and Eric Boersma and Maryam Kavousi and Fauser, {Bart C. J. M.} and Laven, {Joop S. E.} and Sara Baart and Laura Benschop and Laura Brouwers and Ricardo Budde and Suzanne Cannegieter and Veerle Dam and Rene Eijkemans and Fauser, {Bart C. J. M.} and Michel Ferrari and Arie Franx and {de Groot}, Christianne and Gunning, {Marlise N.} and Annemieke Hoek and Erik Koffijberg and Wendy Koster and Mark Kruit and Giske Lagerweij and Joop Laven and Katie Linstra and {van der Lugt}, Aad and Angela Maas and {van den Brink}, {Antoinette Maassen} and Saskia Middeldorp and Moons, {Karel G. M.} and {van Rijn}, Bas and Luuk Scheres and {van der Schouw}, {Yvonne T.} and Eric Steegers and Regine Steegers and Gisela Terwindt and Birgitta Velthuis and Marieke Wermer and Bart Zick and Gerbrand Zoet",

note = "Funding Information: The current study was funded by the Dutch Heart Foundation, grant number?2013T083 (MNG., CM). BCJMF has received fees and grant support from the following organizations (in alphabetic order): Abbott, Controversies in Obstetrics & Gynecology (COGI), Dutch?Heart Foundation (Hartstichting), Dutch Medical Research Counsel (ZonMW), Ferring, London Womens Clinic (LWC), Menogenix, Myovant, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter,?Reproductive Biomedicine Online (RBMO), Teva/Theramex and World Health Organization (WHO). JSEL has received fees and grant support from the following organizations (in alphabetic order): Danone, Dutch Heart Foundation, Euroscreen, Ferring, Roche, Titus Healthcare and ZonMW. CBL has over the most recent 5?year period received fees and grant support from the following organizations (in?alphabetic order): Amsterdam UMC, Ferring, Merck and ZonMW. MK is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Funding Information: The current study was funded by the Dutch Heart Foundation, grant number 2013T083 (MNG., CM). BCJMF has received fees and grant support from the following organizations (in alphabetic order): Abbott, Controversies in Obstetrics & Gynecology (COGI), Dutch Heart Foundation (Hartstichting), Dutch Medical Research Counsel (ZonMW), Ferring, London Womens Clinic (LWC), Menogenix, Myovant, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter, Reproductive Biomedicine Online (RBMO), Teva/Theramex and World Health Organization (WHO). JSEL has received fees and grant support from the following organizations (in alphabetic order): Danone, Dutch Heart Foundation, Euroscreen, Ferring, Roche, Titus Healthcare and ZonMW. CBL has over the most recent 5 year period received fees and grant support from the following organizations (in alphabetic order): Amsterdam UMC, Ferring, Merck and ZonMW. MK is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Publisher Copyright: {\textcopyright} 2019 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd",

year = "2020",

month = feb,

day = "1",

doi = "10.1111/cen.14117",

language = "English",

volume = "92",

pages = "150--158",

journal = "Clinical Endocrinology",

issn = "0300-0664",

publisher = "Wiley-Blackwell",

number = "2",

}

Meun, C, Gunning, MN, Louwers, YV, Peters, H, Roos-Hesselink, J, van Lennep, JR, Rueda Ochoa, O-L, Appelman, Y, Lambalk, N, Boersma, E, Kavousi, M, Fauser, BCJM, Laven, JSE, Baart, S, Benschop, L, Brouwers, L, Budde, R, Cannegieter, S, Dam, V, Eijkemans, R, Fauser, BCJM, Ferrari, M, Franx, A, de Groot, C, Gunning, MN, Hoek, A, Koffijberg, E, Koster, W, Kruit, M, Lagerweij, G, Laven, J, Linstra, K, van der Lugt, A, Maas, A, van den Brink, AM, Middeldorp, S, Moons, KGM, van Rijn, B, Scheres, L, van der Schouw, YT, Steegers, E, Steegers, R, Terwindt, G, Velthuis, B, Wermer, M, Zick, B & Zoet, G 2020, 'The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome', Clinical Endocrinology, vol. 92, no. 2, pp. 150-158. https://doi.org/10.1111/cen.14117

TY - JOUR

T1 - The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome

AU - Meun, Cindy

AU - Gunning, Marlise N.

AU - Louwers, Yvonne, V

AU - Peters, Henrike

AU - Roos-Hesselink, Jolien

AU - van Lennep, Jeanine Roeters

AU - Rueda Ochoa, Oscar-Leonel

AU - Appelman, Yolande

AU - Lambalk, Nils

AU - Boersma, Eric

AU - Kavousi, Maryam

AU - Fauser, Bart C. J. M.

AU - Laven, Joop S. E.

AU - Baart, Sara

AU - Benschop, Laura

AU - Brouwers, Laura

AU - Budde, Ricardo

AU - Cannegieter, Suzanne

AU - Dam, Veerle

AU - Eijkemans, Rene

AU - Fauser, Bart C. J. M.

AU - Ferrari, Michel

AU - Franx, Arie

AU - de Groot, Christianne

AU - Gunning, Marlise N.

AU - Hoek, Annemieke

AU - Koffijberg, Erik

AU - Koster, Wendy

AU - Kruit, Mark

AU - Lagerweij, Giske

AU - Laven, Joop

AU - Linstra, Katie

AU - van der Lugt, Aad

AU - Maas, Angela

AU - van den Brink, Antoinette Maassen

AU - Middeldorp, Saskia

AU - Moons, Karel G. M.

AU - van Rijn, Bas

AU - Scheres, Luuk

AU - van der Schouw, Yvonne T.

AU - Steegers, Eric

AU - Steegers, Regine

AU - Terwindt, Gisela

AU - Velthuis, Birgitta

AU - Wermer, Marieke

AU - Zick, Bart

AU - Zoet, Gerbrand

N1 - Funding Information: The current study was funded by the Dutch Heart Foundation, grant number?2013T083 (MNG., CM). BCJMF has received fees and grant support from the following organizations (in alphabetic order): Abbott, Controversies in Obstetrics & Gynecology (COGI), Dutch?Heart Foundation (Hartstichting), Dutch Medical Research Counsel (ZonMW), Ferring, London Womens Clinic (LWC), Menogenix, Myovant, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter,?Reproductive Biomedicine Online (RBMO), Teva/Theramex and World Health Organization (WHO). JSEL has received fees and grant support from the following organizations (in alphabetic order): Danone, Dutch Heart Foundation, Euroscreen, Ferring, Roche, Titus Healthcare and ZonMW. CBL has over the most recent 5?year period received fees and grant support from the following organizations (in?alphabetic order): Amsterdam UMC, Ferring, Merck and ZonMW. MK is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Funding Information: The current study was funded by the Dutch Heart Foundation, grant number 2013T083 (MNG., CM). BCJMF has received fees and grant support from the following organizations (in alphabetic order): Abbott, Controversies in Obstetrics & Gynecology (COGI), Dutch Heart Foundation (Hartstichting), Dutch Medical Research Counsel (ZonMW), Ferring, London Womens Clinic (LWC), Menogenix, Myovant, OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter, Reproductive Biomedicine Online (RBMO), Teva/Theramex and World Health Organization (WHO). JSEL has received fees and grant support from the following organizations (in alphabetic order): Danone, Dutch Heart Foundation, Euroscreen, Ferring, Roche, Titus Healthcare and ZonMW. CBL has over the most recent 5 year period received fees and grant support from the following organizations (in alphabetic order): Amsterdam UMC, Ferring, Merck and ZonMW. MK is supported by a VENI grant from the Netherlands Organization for Scientific Research (VENI 91616079). Publisher Copyright: © 2019 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd

PY - 2020/2/1

Y1 - 2020/2/1

N2 - OBJECTIVES: Contradictory results have been reported regarding the association between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD). We assessed the cardiometabolic phenotype and prevalence of CVD in middle-aged women with PCOS, compared with age-matched controls from the general population, and estimated 10-year CVD risk and cardiovascular health score.DESIGN: A cross-sectional study.PARTICIPANTS: 200 women aged >45 with PCOS, and 200 age-matched controls.MEASUREMENTS: Anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes. Ten-year Framingham risk score and the cardiovascular health score were calculated, and carotid intima-media thickness (cIMT) was measured.RESULTS: Mean age was 50.5 years (SD = 5.5) in women with PCOS and 51.0 years (SD = 5.2) in controls. Increased waist circumference, body mass index and hypertension were more often observed in women with PCOS (P < .001). In women with PCOS, the prevalence of type II diabetes and metabolic syndrome was not significantly increased and lipid levels were not different from controls. cIMT was lower in women with PCOS (P < .001). Calculated cardiovascular health and 10-year CVD risk were similar in women with PCOS and controls.CONCLUSIONS: Middle-aged women with PCOS exhibit only a moderately unfavourable cardiometabolic profile compared to age-matched controls, even though they present with an increased BMI and waist circumference. Furthermore, we found no evidence for increased (10-year) CVD risk or more severe atherosclerosis compared with controls from the general population. Long-term follow-up of women with PCOS is necessary to provide a definitive answer concerning long-term risk for CVD.

AB - OBJECTIVES: Contradictory results have been reported regarding the association between polycystic ovary syndrome (PCOS) and cardiovascular disease (CVD). We assessed the cardiometabolic phenotype and prevalence of CVD in middle-aged women with PCOS, compared with age-matched controls from the general population, and estimated 10-year CVD risk and cardiovascular health score.DESIGN: A cross-sectional study.PARTICIPANTS: 200 women aged >45 with PCOS, and 200 age-matched controls.MEASUREMENTS: Anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes. Ten-year Framingham risk score and the cardiovascular health score were calculated, and carotid intima-media thickness (cIMT) was measured.RESULTS: Mean age was 50.5 years (SD = 5.5) in women with PCOS and 51.0 years (SD = 5.2) in controls. Increased waist circumference, body mass index and hypertension were more often observed in women with PCOS (P < .001). In women with PCOS, the prevalence of type II diabetes and metabolic syndrome was not significantly increased and lipid levels were not different from controls. cIMT was lower in women with PCOS (P < .001). Calculated cardiovascular health and 10-year CVD risk were similar in women with PCOS and controls.CONCLUSIONS: Middle-aged women with PCOS exhibit only a moderately unfavourable cardiometabolic profile compared to age-matched controls, even though they present with an increased BMI and waist circumference. Furthermore, we found no evidence for increased (10-year) CVD risk or more severe atherosclerosis compared with controls from the general population. Long-term follow-up of women with PCOS is necessary to provide a definitive answer concerning long-term risk for CVD.

KW - cardiovascular disease (7)

KW - polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=85075478793&partnerID=8YFLogxK

U2 - 10.1111/cen.14117

DO - 10.1111/cen.14117

M3 - Article

C2 - 31638273

SN - 0300-0664

VL - 92

SP - 150

EP - 158

JO - Clinical Endocrinology

JF - Clinical Endocrinology

IS - 2

ER -

The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this